Terminalia arjuna and heart failure

What 3 graded rows on terminalia arjuna agree on for heart failure, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Terminalia arjuna page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Terminalia arjuna page, with its PubMed record.

Supplement

Terminalia arjuna Choose another

3 rows · 649 people

Split. 1 row found an improvement, 1 found no difference and 1 had mixed results.

No difference or mixed

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside. Outlined: mixed results.

From the rows

Trial sizeHow longWhen publishedGrade

The best-graded row, grade B, is a randomized trial of 100 people (2016) and found no difference.

The row that found no difference was larger: 100 people, against 12 people for the row that found an improvement.

The row that found no difference ran longer (3 months) than the row that found an improvement (2 weeks).

The row that found no difference is newer (2016) than the row that found an improvement (1995).

The best grade is B among the row that found no difference, and D among the row that found an improvement.

1 row with mixed results is left out of this comparison.

1 improved · 1 no difference · 1 mixed

Grade DSymptoms and echocardiography in refractory heart failure · Improved
Crossover RCT · n 12 · 1995 · Patients with NYHA class IV heart failure, mostly dilated cardiomyopathy
500 mg every 8 hours · 2 weeks per treatment
Ejection fraction rose (35% vs 30%) and NYHA class, ventricular volumes and stroke volume improved versus placebo.
Row on the Terminalia arjuna page · PubMed 7649665 (opens PubMed)
Grade BEjection fraction in chronic heart failure · No difference
RCT · n 100 · 2016 · Patients with NYHA class II heart failure and ejection fraction 40% or less on standard drugs
750 mg twice daily · 12 weeks
No change in ejection fraction versus placebo (24.3% vs 25.5%, p=0.4) or in secondary outcomes except red-cell catalase; post-hoc subgroup gains in walk distance and symptoms.
Row on the Terminalia arjuna page · PubMed 26988798 (opens PubMed)
Grade CLeft-ventricular mass, ejection fraction, lipids and blood pressure in heart failure · Mixed
Meta-analysis · n 537 · 2026 · Adults with heart failure in 9 trials
Varied · Varied
Left-ventricular mass fell (mean difference −44.3) and HDL rose (+3.5), but ejection fraction improved only non-significantly (+1.85, p=0.1) and blood pressure, triglycerides and LDL did not change.
Row on the Terminalia arjuna page · PubMed 42389976 (opens PubMed)